Table 5.
Correlation between the levels of HA, circulating CD14+CD204+ M2-like monocytes, CEA, and CA15-3 and clinicopathological characteristics of breast cancer patients
| Characteristics | NO. | HA Median (P25-P75) |
p | CD14+CD204+ (%) (Mean ± SD) |
p | CEA Median (P25-P75) |
p | CA15-3 Median (P25-P75) |
p |
|---|---|---|---|---|---|---|---|---|---|
| Age(years) | |||||||||
| ≤50 >50 |
38 43 |
55.22 (51.10-78.50) 66.98 (58.06-86.88) |
0.148 | 10.53 ± 3.02 11.46 ± 2.42 |
0.130 | 1.52 (0.98-2.21) 1.72 (1.16-2.41) |
0.237 | 13.60(10.16-17.69) 10.21 (8.10-15.00) |
0.071 |
| Tumor size(cm) | |||||||||
| ≤2.0 >2.0 |
34 47 |
65.05 (53.41-80.72) 61.22 (50.74-82.78) |
0.528 | 10.75 ± 2.42 11.22 ± 2.96 |
0.448 | 1.45 (1.01-1.88) 1.61 (1.15-2.50) |
0.089 | 11.20 (8.37-15.24) 12.15 (8.14-17.14) |
0.639 |
| TNM stage | |||||||||
| 0-I | 29 | 58.61(52.31-73.38) | 9.70 ± 2.17 | 1.35(0.94-2.10) | 10.30(8.33-14.47) | ||||
| II | 41 | 61.63(51.22-87.61) | 0.472 | 11.35 ± 2.69 | 0.000* | 1.76(1.38-2.41) | 0.113 | 12.87(9.35-17.94) | 0.267 |
| III or higher | 11 | 70.36(50.60-154.7) | 13.26 ± 2.64 | 1.49(0.99-4.83) | 12.63(6.72-17.40) | ||||
| Histology type | |||||||||
| Ductal Others |
54 27 |
61.43 (53.34-80.86) 64.19 (50.08-93.13) |
0.411 | 10.85 ± 2.64 11.36 ± 2.96 |
0.432 | 1.60 (1.11-2.21) 1.49 (1.03-2.47) |
0.912 | 12.04 (8.21-17.34) 10.38 (8.43-14.88) |
0.465 |
| Histology differentiation | |||||||||
| Well-Moderate Poor |
38 43 |
55.22 (50.66-71.21) 72.89 (56.00-105.4) |
0.007* | 9.39 ± 2.14 12.46 ± 2.40 |
0.000* | 1.54 (1.01-2.50) 1.59 (1.10-2.02) |
0.913 | 11.56 (8.53-15.75) 11.50 (8.10-17.14) |
0.962 |
| N status | |||||||||
| N0 | 43 | 61.22 (52.31-78.30) | 0.623 | 9.82 ± 2.43 | 0.000* | 1.54 (1.08-2.39) | 0.233 | 10.92 (8.07-15.23) | 0.075 |
| N1-3 | 38 | 63.21 (51.07-87.98) | 12.38 ± 2.45 | 1.66 (1.13-2.36) | 13.36 (8.84-18.53) | ||||
| ER | |||||||||
| Positive Negative |
53 28 |
59.65 (52.31-74.89) 71.98 (51.07-110.7) |
0.207 | 9.94 ± 2.32 13.07 ± 2.28 |
0.000* | 1.70 (1.10-2.42) 1.50 (1.04-1.99) |
0.410 | 11.50 (8.46-16.34) 11.41 (7.16-16.94) |
0.792 |
| PR | |||||||||
| Positive Negative |
48 33 |
61.17 (51.46-77.84) 64.19 (52.20-95.73) |
0.651 | 10.57 ± 2.71 11.68 ± 2.70 |
0.074 | 1.63 (1.07-2.37) 1.54 (1.08-2.49) |
0.977 | 11.49 (8.50-15.87) 12.05 (7.19-17.61) |
0.916 |
| HER2 | |||||||||
| Positive Negative |
22 59 |
56.11 (50.09-73.82) 64.19 (53.76-86.88) |
0.110 | 11.33 ± 3.12 10.91 ± 2.61 |
0.533 | 1.31 (1.01-2.44) 1.61 (1.11-2.38) |
0.585 | 10.65 (7.76-16.63) 11.64 (8.48-16.27) |
0.381 |
| Ki67 | |||||||||
| <20% ≥20% |
36 45 |
65.39 (52.95-77.30) 59.65 (50.78-84.83) |
0.540 | 10.48 ± 2.44 11.46 ± 2.92 |
0.111 | 1.54 (1.07-2.42) 1.72 (1.07-2.24) |
0.974 | 12.05 (9.64-16.29) 11.50 (4.07-16.47) |
0.272 |
*: p < 0.05. ER: Estrogen receptor, PR: Progesterone receptor, HER2: Human epidermal factor 2.